DBV reports positive Phase 3 data for peanut allergy therapy in toddlers (DBVT)
Professor25/iStock via Getty Images DBV Technologies (NASDAQ:DBVT) reported positive two-year data from an ongoing Phase 3 study extension for its peanut allergy treatment Viaskin Peanut in toddlers aged one to three years old. The…
